Full Press Release Details
FRIENDSWOOD, Texas,July 9, 2026/PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2026, after the close of market on Thursday, July 30, 2026.
Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
Webcast DetailsThe live webcast can be accessed here:https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe, or via the webcast link on the Investor Relations page of the Company's website:https://ir.castlebiosciences.com/. Please access the webcast at least 10 minutes before the start time. A replay of the webcast will be available following its conclusion.
There will be a brief Question and Answer session following management commentary.
About Castle BiosciencesCastle Biosciences (Nasdaq:CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visitwww.CastleBiosciences.comand connect with us onLinkedIn,Instagram,FacebookandX.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeqare trademarks of Castle Biosciences, Inc.